Version 1
: Received: 11 July 2023 / Approved: 12 July 2023 / Online: 12 July 2023 (10:56:25 CEST)
How to cite:
Sun, K.-H.; Lee, M.-Y.; Jeon, Y.-J. Inhibition of Phagocytosis by Silibinin in Mouse Macrophages. Preprints2023, 2023070826. https://doi.org/10.20944/preprints202307.0826.v1
Sun, K.-H.; Lee, M.-Y.; Jeon, Y.-J. Inhibition of Phagocytosis by Silibinin in Mouse Macrophages. Preprints 2023, 2023070826. https://doi.org/10.20944/preprints202307.0826.v1
Sun, K.-H.; Lee, M.-Y.; Jeon, Y.-J. Inhibition of Phagocytosis by Silibinin in Mouse Macrophages. Preprints2023, 2023070826. https://doi.org/10.20944/preprints202307.0826.v1
APA Style
Sun, K. H., Lee, M. Y., & Jeon, Y. J. (2023). Inhibition of Phagocytosis by Silibinin in Mouse Macrophages. Preprints. https://doi.org/10.20944/preprints202307.0826.v1
Chicago/Turabian Style
Sun, K., Min-Young Lee and Young-Jin Jeon. 2023 "Inhibition of Phagocytosis by Silibinin in Mouse Macrophages" Preprints. https://doi.org/10.20944/preprints202307.0826.v1
Abstract
This study investigated the effects of silibinin, derived from milk thistle (Silybum marianum), on lipopolysaccharide (LPS)-induced morphological changes in mouse macrophages. Silibinin was treated at various doses and time points to assess its effects on macrophage activation including morphological changes and phagocytosis. Silibinin effectively inhibited LPS-induced pseudopodia formation and size increase, while unstimulated cells remained round. Silibinin's impact on phagocytosis was dose- and time-dependent, showing a decrease. We explored its mechanism of action on kinases using a MAPK array. Among the three MAPK family members tested, silibinin had a limited effect on JNK and p38 but significantly inhibited ERK1/2 and related RSK1/2. Silibinin also inhibited MKK6, AKT3, MSK2, p70S6K, and GSK-3β. These findings highlight silibinin's potent inhibitory effects on phagocytosis and morphological changes in macrophages. We suggest its potential as an anti-inflammatory agent due to its ability to target key inflammatory pathways involving ERK1/2 and related kinases. Overall, this study demonstrates the promising therapeutic properties of silibinin in modulating macrophage function and inflammation.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.